相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial
Keith S. Kaye et al.
CLINICAL INFECTIOUS DISEASES (2019)
AmpC -lactamase-producing Enterobacterales: what a clinician should know
Simone Meini et al.
INFECTION (2019)
Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Characterization of Isolates Associated with Emergence of OXA-48-Producing Klebsiella pneumoniae in Croatia
Marko Jelic et al.
MICROBIAL DRUG RESISTANCE (2018)
In Vitro Activity of Ceftolozane-Tazobactam against Enterobacter cloacae Complex Clinical Isolates with Different β-Lactam Resistance Phenotypes
Frederic Robin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party
Peter M. Hawkey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms
Lacie McKamey et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature
B. Grabein et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Cooccurrence of Multiple AmpC beta-Lactamases in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis in Tunisia
Thouraya Cherif et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis
Patrick N. A. Harris et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates
Nan-Yao Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
First Report of an OXA-48-Producing Multidrug-Resistant Proteus mirabilis Strain from Gaza, Palestine
Liang Chen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Fosfomycin versu meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial
Clara Rosso-Fernandez et al.
BMJ OPEN (2015)
Microbiological Screening Is Necessary to Distinguish Carriers of Plasmid-Mediated AmpC Beta-Lactamase-Producing Enterobacteriaceae and Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae because of Clinical Similarity
Anna Conen et al.
PLOS ONE (2015)
Detection of CMY-99, a Novel Acquired AmpC-Type β-Lactamase, and VIM-1 in Proteus mirabilis Isolates in Bulgaria
Ines Schneider et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Antibiotic Trapping by Plasmid-Encoded CMY-2 β-Lactamase Combined with Reduced Outer Membrane Permeability as a Mechanism of Carbapenem Resistance in Escherichia coli
Wil H. F. Goessens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
EUCAST expert rules in antimicrobial susceptibility testing
R. Leclercq et al.
CLINICAL MICROBIOLOGY AND INFECTION (2013)
Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?
P. N. A. Harris et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo
Jose M. Rodriguez-Martinez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Evolution and Spread of a Multidrug-Resistant Proteus mirabilis Clone with Chromosomal AmpC-Type Cephalosporinases in Europe
M. M. D'Andrea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae
Indran Balakrishnan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Phenotypic and Biochemical Comparison of the Carbapenem-Hydrolyzing Activities of Five Plasmid-Borne AmpC β-Lactamases
Hedi Mammeri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Emergence of Proteus mirabilis Isolates Producing TEM-52 Extended-Spectrum beta-Lactamases in Croatia
Sanda Sardelic et al.
CHEMOTHERAPY (2010)
Prevalence of acquired AmpC β-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007
C. Mata et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin
Matthew E. Falagas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Detecting VIM-1 Production in Proteus mirabilis by an Imipenem-Dipicolinic Acid Double Disk Synergy Test
V. Miriagou et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia
Marija Tonkic et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2010)
Reduced Susceptibility to Cefepime among Escherichia coli Clinical Isolates Producing Novel Variants of CMY-2 β-Lactamase
Yohei Doi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase: epidemiology and clinical management
Francesco Luzzaro et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Temocillin revived
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Molecular survey of β-lactamases conferring resistance to newer β-lactams in Enterobacteriaceae isolates from Polish hospitals
Joanna Empel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Dissemination of the CTX-M-25 family β-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel
Shiri Navon-Venezia et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
CMY-16, a novel acquired AmpC-type β-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy
MM D'Andrea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type β-lactamase
CI Kang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Four variants of the Citrobacter freundii AmpC-type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland
E Literacka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Plasmid-encoded functions compensate for the biological cost of AmpC overexpression in a clinical isolate of Salmonella typhimurium
A Hossain et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Insertion sequence ISEcp1B is involved in expression and mobilization of a blaCTX-M β-lactamase gene
L Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Characterization of CMY-type β-lactamases in clinical strains of Proteus mirabilis and Klebsiella pneumoniae isolated in four hospitals in the Paris area
D Decré et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR
FJ Pérez-Pérez et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Outer membrane protein change combined with co-existing TEM-1 and SHV-1 β-lactamases lead to false identification of ESBL-producing Klebsiella pneumoniae
TL Wu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)